The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Lefkovits et al., N Engl J Med 332(23):1553-1559 June 8, 1995.

Correction
PreviousPrevious
Volume 334:675 March 7, 1996 Number 10

Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Lefkovits, J.
Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine . On page 1556, the chemical structures shown in Figure 3 are incorrect. The correct figure and legend appear below.

Figure Removed (Available Only in the Full Text)
View larger version (9K):
[in this window]
[in a new window]
  		Figure 3. Chemical Structures of Some Inhibitors of Platelet Glycoprotein IIb/IIIa Receptors That Have Been Evaluated in Clinical Studies.

MK-852 is a cyclic RGD peptide, lamifiban is a peptide derivative, tirofiban is a nonpeptide, and xemilofiban is an orally active inhibitor of glycoprotein IIb/IIIa receptors. Ac denotes acetyl group.

 



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.